Analysis underscores value of piflufolastat F 18 in recurrent prostate cancer with low PSA levels
The data come from a sub-analysis of the pivotal phase 3 CONDOR trial of the PSMA-targeted radiopharmaceutical piflufolastat F 18 in men with suspected recurrence of prostate cancer.
Findings from a secondary analysis of the phase 3 CONDOR trial (NCT03739684) shared during the 2023 ASCO GU Cancers Symposium showed that piflufolastat F 18 (Pylarify) given before positron emission tomography (PET) scanning led to changes in intended management in 39.1% of patients with PSA level below 0.5 ng/mL.1,2
“These data in the subset of men with low PSA levels reinforces the impact and potential role of piflufolastat F 18 in informing patient management decisions in real-world scenarios,” Jean-Claude Provost, MD.
In the analysis, 74.1% (20/27) of patients had a change in management which led to an escalation of treatment from local salvage therapy to systemic therapy, or a shift from observation to initiating treatment. In 18 of the 20 patients who had an intensification of treatment, piflufolastat F 18 identified lesions.
The clinical utility of piflufolastat F18 PET/CT is supported by this analysis in men with low PSA levels that range from 0.2ng/mL-0.5 ng/mL.
“[Piflufolastat F 18] has the potential to contribute meaningful and actionable information that can be used to personalize treatment plans in men with low PSA levels,” said Frederic Pouliot, MD, Hospitalier Universitaire de Québec-Université Laval, in a presentation of these data. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to assess the relevance and applicability of intended treatment management plans.”
Piflufolastat F 18 is a prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical and is approved in the United States for imaging patients with prostate cancer at the time of initial staging and at disease recurrence.
Investigators reviewed data from a subset of 69 patients from the CONDOR trial who had a PSA level below 0.5 ng/mL.1 In the study, patients received a single dose injection of piflufolastat F 18 prior to PET imaging and completed pre- and post-imaging questionnaires about the intended management of their prostate cancer.
The goal of the study was to evaluate the clinical utility of piflufolastat F 18 scanning in men with very low/low PSA levels (< 0.5 ng/mL). Researchers assessed the primary end point of correct localization rate and the secondary end points of percentage of participants with a change in intended prostate cancer treatment plans due to piflufolastat F 18 imaging results, the change from pre- to post- piflufolastat F 18 dosing in blood pressure and heart rate, collection of concomitant medications, and collection of medical procedures.
Male patients 18 years of age and older were enrolled in the trial if they had histopathologically confirmed prostate adenocarcinoma with suspected recurrence of prostate cancer based on rising PSA after definitive therapy, negative or equivocal findings for prostate cancer on conventional imaging performed as part of standard of care workup within 60 days prior to the start of the study, and a life expectancy of 6 months or more.
In the trial, 208 men with a median baseline PSA of 0.8 ng/mL (range, 0.2-98.4 ng/mL) were enrolled and given piflufolastat F 18. Findings revealed that the correct localization rate was 84.8%-87.0% (lower bound of 95% CI, 77.8-80.4), and the disease detection rate was 59%-66%.3
The trial achieved its primary end point of demonstrating disease localization in the setting of negative standard imaging. Additionally, piflufolastat F 18 led to clinically meaningful and actionable information, supporting the utility of piflufolastat F 18 to localize disease in male patients with recurrent prostate cancer.
“We had observed in the CONDOR phase 3 study of men with biochemically recurrent prostate cancer, that nearly two-thirds of patients had their treatment plan altered, attributed to learnings from the scan itself,” stated Jean-Claude Provost, MD, chief medical officer of Lantheus, in a press release. “These data in the subset of men with low PSA levels reinforces the impact and potential role of piflufolastat F 18 in informing patient management decisions in real-world scenarios.”
REFERENCES:
1. Pouliot F, Gorin MA, Rowe SP. Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. J Clin Oncol 41, 2023 (suppl 6; abstr 61). doi: 10.1200/JCO.2023.41.6_suppl.61
2. Lantheus presents data reinforcing real-world clinical utility of piflufolastat F 18 PET scanning in men with recurrent prostate cancer and low PSA levels. News release. Lantheus Holdings, Inc. February 16, 2023. Accessed February 20, 2023. https://bit.ly/3YJ0sFa
3. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
